Skip to content
Edarbi(azilsartan)
Edarbi, Edarbyclor (azilsartan) is a small molecule pharmaceutical. Azilsartan was first approved as Edarbi on 2011-02-25. It is used to treat hypertension in the USA. It has been approved in Europe to treat hypertension. It is known to target type-1 angiotensin II receptor.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
cardiovascular diseasesD002318
Trade Name
FDA
EMA
Edarbi (generic drugs available since 2022-07-20)
Combinations
Edarbyclor
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Azilsartan kamedoxomil
Tradename
Company
Number
Date
Products
EDARBIAzurityN-200796 RX2011-02-25
2 products, RLD, RS
Azilsartan kamedoxomil
+
Chlorthalidone
Tradename
Company
Number
Date
Products
EDARBYCLORAzurityN-202331 RX2011-12-20
2 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
edarbiNew Drug Application2020-06-05
edarbyclorNew Drug Application2020-06-05
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
hypertensionEFO_0000537D006973I10
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Azilsartan Kamedoxomil / Chlorthalidone, Edarbyclor, Azurity
93872492031-07-01U-3
91692382030-02-04DP
Azilsartan Kamedoxomil, Edarbi, Azurity
90669362028-03-26DP
71575842025-05-22DP
75729202025-01-07DPU-3
ATC Codes
C: Cardiovascular system drugs
— C09: Agents acting on the renin-angiotensin system
— C09C: Angiotensin ii receptor blockers (arbs), plain
— C09CA: Angiotensin ii receptor blockers (arbs), plain
— C09CA09: Azilsartan medoxomil
— C09D: Angiotensin ii receptor blockers (arbs), combinations
— C09DA: Angiotensin ii receptor blockers (arbs) and diuretics
— C09DA09: Azilsartan medoxomil and diuretics
HCPCS
No data
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameAZILSARTAN
INNazilsartan
Description
Azilsartan is an angiotensin II receptor antagonist used in the treatment of hypertension, developed by Takeda. It is marketed in tablet form under the brand name Edarbi as the prodrug azilsartan medoxomil.
Classification
Small molecule
Drug classangiotensin II receptor antagonists
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2noc(=O)[nH]2)cc1
Identifiers
PDB—
CAS-ID147403-03-0
RxCUI1091643
ChEMBL IDCHEMBL57242
ChEBI ID68850
PubChem CID9825285
DrugBankDB08822
UNII IDF9NUX55P23 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
AGTR1
AGTR1
Organism
Homo sapiens
Gene name
AGTR1
Gene synonyms
AGTR1A, AGTR1B, AT2R1, AT2R1B
NCBI Gene ID
185
Protein name
type-1 angiotensin II receptor
Protein synonyms
Angiotensin II type-1 receptor, AT1 receptor, AT1AR, AT1BR, type-1B angiotensin II receptor
Uniprot ID
Q8TBK4
Mouse ortholog
Agtr1b (11608)
type-1 angiotensin II receptor B (P29755)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 916 documents
View more details
Safety
Black-box Warning
Black-box warning for: Edarbi, Edarbyclor
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details